Oxcarbazepine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Oxcarbazepine

Examples of brand names: Trileptal [DE]

ATC code: N03AF02

Main use (for orientation): Epilepsy

Documented research summary

Findings are model-dependent: an acute mouse experiment shows enhanced anticonvulsant activity with CBD, while a subchronic 3-mercaptopropionic-acid rat experiment shows more resistant seizures with CBD plus oxcarbazepine ED50. A pain case with full-spectrum CBD plus CBG does not allow isolated attribution. UAB 2023 shows no significant oxcarbazepine concentration signal (n=28, p=0.4701), not equivalence or assurance of safety.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

4 separately recorded findings. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0067

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.4701.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=28.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

CBD – laboratory and animal studies

Finding ID: B0334

Type of result: Preclinical signal

Observation: After repeated CBD plus oxcarbazepine ED50, 10/10 surviving rats showed resistant seizures; CCO plus vehicle control 5/10, oxcarbazepine without CBD 7/10. Significance versus vehicle/CBD alone; do not present as a proven difference versus oxcarbazepine 7/10.

Mechanism: Preclinical interaction; docking/pharmacodynamic/pharmacokinetic explanations hypothetical.

Study type: Subchronic 3-mercaptopropionic-acid rat model plus docking

Context studied: CBD 200 mg/kg orally, oxcarbazepine 12 mg/kg intraperitoneally, every 12 hours for 10 trials; resistance test in 10 survivors.

Clinical interpretation: Model-dependent negative finding; not a human risk prediction.

Limitations and uncertainties: High animal dose, survivor selection; no human pharmacokinetic evidence. Do not interpret 41% mortality with the combination as a statistically established increase over oxcarbazepine alone.

Original sources for this finding: Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model. [C_PR_41050418]

CBD – laboratory and animal studies

Finding ID: B0335

Type of result: Preclinical signal, abstract level

Observation: CBD enhanced oxcarbazepine anticonvulsant effects in the maximal-electroshock mouse model.

Mechanism: Acute preclinical pharmacodynamic/pharmacokinetic interaction possible.

Study type: Acute mouse experiment with serum/brain concentrations

Context studied: Socała 2019; abstract reports concentration changes in several pairs, no oxcarbazepine-specific figures extracted.

Clinical interpretation: Do not merge with the subchronic negative model.

Limitations and uncertainties: Full text inaccessible; no human extrapolation.

Original sources for this finding: Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. [CA_P_31377197]

Full-spectrum CBD plus CBG isolate – clinical signals

Finding ID: B0336

Type of result: Uncontrolled case signal

Observation: 57-year-old female patient pain-free after 15 days; oxcarbazepine reduced from 300 mg three times to twice daily, pregabalin/topical treatments/laser stopped.

Mechanism: Clinical adjunctive therapy; isolated interaction cannot be determined.

Study type: Single case of trigeminal/postherpetic pain

Context studied: Sublingual products containing CBD 3000 mg/30 ml plus CBG 1500 mg/30 ml; actual daily dose not stated; several concurrent therapies and water exercises.

Clinical interpretation: Not CBD- or CBG-specific synergy or safety evidence.

Limitations and uncertainties: Mixed product, multiple interventions, no pharmacokinetics or control; no reported adverse effects in 1 person does not establish safety.

Original sources for this finding: Use of Cannabidiol and Cannabigerol in the Treatment of Trigeminal Neuralgia and Postherpetic Pain. [C_PR_41281696]

References and access status

[C_LABEL_D0042] OXTELLAR XR (OXCARBAZEPINE) TABLET [SUPERNUS PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: SUPERNUS PHARMACEUTICALS, INC.

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_41050418] Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model.

Original source / bibliographic reference

Authors: Fuentes-Mejia M, Fallico MJ, Talevi A, Gavernet L, Orozco-Suárez SA, Rocha L.

Year: 2025

Source type: Primary source, full text read

DOI: 10.3389/fphar.2025.1644018

PMID: 41050418

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_41281696] Use of Cannabidiol and Cannabigerol in the Treatment of Trigeminal Neuralgia and Postherpetic Pain.

Original source / bibliographic reference

Authors: Souza SEDS, Castro ABB, Cavalcante AMDS, Gomes AKP, Brizeno LAC, Forte CPF, Dantas TS.

Year: 2025

Source type: Primary source, full text read

DOI: 10.4103/ccd.ccd_280_24

PMID: 41281696

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[CA_P_31377197] Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.

Original source / bibliographic reference

Authors: Socała K, Wyska E, Szafarz M, Nieoczym D, Wlaź P.

Year: 2019

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1016/j.neuropharm.2019.107733

PMID: 31377197

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility